Director, DMPK

Company Summary:

Atavistik Bio is a privately-held biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs, with a focus on oncology. Our proprietary AMPS™ platform allows us to rapidly unlock functional cryptic pockets across a broad range of target classes to accelerate the development of groundbreaking medicines. We have rapidly established an emerging pipeline of allosteric therapeutics with the potential to achieve superior efficacy and tolerability profiles by leveraging the power of allostery. Atavistik Bio is led by an experienced team of drug hunters with a proven track record of developing marketed small molecule therapies and supported by top-tier investors, including The Column Group, Nextech Invest, and Lux Capital. To learn more, visit us at atavistikbio.com and follow us on LinkedIn.

Position Summary:

We are seeking a strategic and creative Director, DMPK, to join our R&D group and work with an enthusiastic team of highly skilled scientists in a fast-paced environment. Reporting to the Senior VP, Drug Discovery, this individual will be responsible for the design, execution, and interpretation of non-clinical DMPK, and toxicology studies. This work supports the progression of therapies from late discovery through first in human and proof of concept clinical studies. This is a great opportunity to build an efficient DMPK function while being part of an exciting early-stage company. 

• Representative DMPK leader as a member of preclinical and IND-enabling teams.
• Function as a key member of Atavistik Bio’s scientific leadership team, providing scientific expertise, strategic planning, and goal-oriented execution.
• Effectively communicate scientific planning, progress and results to executive leadership, R&D teams, and external audiences. Additionally, build and develop appropriate relationships with key opinion leaders and SAB members.
• Propose ADME/PK, biodistribution and PK-PD approaches at team discussions of high impact on project progression.
• Identify and manage consultants and vendors to support ADME, PK and PK/PD studies.
• Contribute to candidate selection, development strategy, and coordinate IND-enabling study reports.
• Partner with the discovery group to optimize preclinical models and inform on first in human clinical dosing strategies.
• Review preclinical study reports, in conjunction with Pharmacokinetics/DMPK and prepare regulatory submission documentation.
• Author DMPK, nonclinical toxicology and biomarker sections of regulatory documents.
• Collaborate cross functionally with all relevant areas to support strategic objectives
• Communicate status updates and program issues to appropriate team members.

• PhD., Pharm. D. or equivalent training in pharmacokinetics, pharmaceutical sciences, or related disciplines.
• 5 years of experience in bio/pharmaceutical industry, combined with drug development
• Excellent communication and collaborative skills to work on project teams with chemists, biologists and platform scientists. 
• Highly organized, self-motivated with a desire to succeed in a fast-paced organization
• Experience with regulatory submissions for small molecules with a focus on preclinical and early clinical development strategy and execution.
• Experience in nonclinical toxicology is a plus.
• Solid understanding of drug metabolism, bioanalysis, pharmacokinetics, preclinical pharmacology, PK/PD modeling and clinical study designs.
• Expertise managing CROs, GLP and other regulated activities.
• Ability to operate objectively and independently as a leader and as a member of a team.
• Must be able to work on multiple projects simultaneously.